For operable NSCLC with high tumor expression of PD‐L1, ICI monotherapy can be considered as neoadjuvant therapy, but the actual curative effect remains to be determined in large‐scale phase III clinical trials. Here, CD274 is linked to non-small cell lung carcinoma.